---
reference_id: "PMID:26092914"
title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
authors:
- Wingerchuk DM
- Banwell B
- Bennett JL
- Cabre P
- Carroll W
- Chitnis T
- de Seze J
- Fujihara K
- Greenberg B
- Jacob A
- Jarius S
- Lana-Peixoto M
- Levy M
- Simon JH
- Tenembaum S
- Traboulsee AL
- Waters P
- Wellik KE
- Weinshenker BG
- International Panel for NMO Diagnosis
journal: Neurology
year: '2015'
doi: 10.1212/WNL.0000000000001729
content_type: abstract_only
---

# International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
**Authors:** Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis
**Journal:** Neurology (2015)
**DOI:** [10.1212/WNL.0000000000001729](https://doi.org/10.1212/WNL.0000000000001729)

## Content

1. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 
2015 Jun 19.

International consensus diagnostic criteria for neuromyelitis optica spectrum 
disorders.

Wingerchuk DM(1), Banwell B(2), Bennett JL(2), Cabre P(2), Carroll W(2), Chitnis 
T(2), de Seze J(2), Fujihara K(2), Greenberg B(2), Jacob A(2), Jarius S(2), 
Lana-Peixoto M(2), Levy M(2), Simon JH(2), Tenembaum S(2), Traboulsee AL(2), 
Waters P(2), Wellik KE(2), Weinshenker BG(1); International Panel for NMO 
Diagnosis.

Author information:
(1)From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), 
Mayo Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; 
the Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the 
Department of Neurology (T.C.), Massachusetts General Hospital, Boston; the 
Department of Neurology (J.d.S.), Strasbourg University, France; the Department 
of Multiple Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of 
Medicine, Sendai, Japan; the Departments of Neurology and Neurotherapeutics 
(B.G.), University of Texas Southwestern Medical Center, Dallas; The Walton 
Centre NHS Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, 
Department of Neurology (S.J.), University Hospital Heidelberg, Germany; the 
Center for Multiple Sclerosis Investigation (M.L.-P.), Federal University of 
Minas Gerais Medical School, Belo Horizonte, Brazil; the Department of Neurology 
(M.L.), Johns Hopkins University, Baltimore, MD; Portland VA Medical Center and 
Oregon Health and Sciences University (J.H.S.), Portland; the Department of 
Neurology (S.T.), National Pediatric Hospital Dr. Juan P. Garrahan, Buenos 
Aires, Argentina; the Department of Medicine (A.L.T.), University of British 
Columbia, Vancouver, Canada; Nuffield Department of Clinical Neurosciences 
(P.W.), University of Oxford, UK; and the Department of Neurology (B.G.W.), Mayo 
Clinic, Rochester, MN. wingerchuk.dean@mayo.edu weinb@mayo.edu.
(2)From the Departments of Neurology (D.M.W.) and Library Services (K.E.W.), 
Mayo Clinic, Scottsdale, AZ; the Children's Hospital of Philadelphia (B.B.), PA; 
the Departments of Neurology and Ophthalmology (J.L.B.), University of Colorado 
Denver, Aurora; the Service de Neurologie (P.C.), Centre Hospitalier 
Universitaire de Fort de France, Fort-de-France, Martinique; Department of 
Neurology (W.C.), Sir Charles Gairdner Hospital, Perth, Australia; the 
Department of Neurology (T.C.), Massachusetts General Hospital, Boston; the 
Department of Neurology (J.d.S.), Strasbourg University, France; the Department 
of Multiple Sclerosis Therapeutics (K.F.), Tohoku University Graduate School of 
Medicine, Sendai, Japan; the Departments of Neurology and Neurotherapeutics 
(B.G.), University of Texas Southwestern Medical Center, Dallas; The Walton 
Centre NHS Trust (A.J.), Liverpool, UK; the Molecular Neuroimmunology Group, 
Department of Neurology (S.J.), University Hospital Heidelberg, Germany; the 
Center for Multiple Sclerosis Investigation (M.L.-P.), Federal University of 
Minas Gerais Medical School, Belo Horizonte, Brazil; the Department of Neurology 
(M.L.), Johns Hopkins University, Baltimore, MD; Portland VA Medical Center and 
Oregon Health and Sciences University (J.H.S.), Portland; the Department of 
Neurology (S.T.), National Pediatric Hospital Dr. Juan P. Garrahan, Buenos 
Aires, Argentina; the Department of Medicine (A.L.T.), University of British 
Columbia, Vancouver, Canada; Nuffield Department of Clinical Neurosciences 
(P.W.), University of Oxford, UK; and the Department of Neurology (B.G.W.), Mayo 
Clinic, Rochester, MN.

Comment in
    Neurology. 2015 Jul 14;85(2):118-9. doi: 10.1212/WNL.0000000000001749.
    Mult Scler Relat Disord. 2018 Feb;20:153. doi: 10.1016/j.msard.2018.01.022.

Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from 
multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin 
G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and 
spinal cord involvement but more restricted or more extensive CNS involvement 
may occur. The International Panel for NMO Diagnosis (IPND) was convened to 
develop revised diagnostic criteria using systematic literature reviews and 
electronic surveys to facilitate consensus. The new nomenclature defines the 
unifying term NMO spectrum disorders (NMOSD), which is stratified further by 
serologic testing (NMOSD with or without AQP4-IgG). The core clinical 
characteristics required for patients with NMOSD with AQP4-IgG include clinical 
syndromes or MRI findings related to optic nerve, spinal cord, area postrema, 
other brainstem, diencephalic, or cerebral presentations. More stringent 
clinical criteria, with additional neuroimaging findings, are required for 
diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. 
The IPND also proposed validation strategies and achieved consensus on pediatric 
NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.

Â© 2015 American Academy of Neurology.

DOI: 10.1212/WNL.0000000000001729
PMCID: PMC4515040
PMID: 26092914 [Indexed for MEDLINE]